Information about Botox by Allergan

Vistabel is a trade name used in several European countries for an Allergan/AbbVie botulinum toxin type A medicine intended for aesthetic use. It belongs to the same botulinum toxin product family associated with the Botox name, but brand names and authorised uses can differ between countries.

For UK patients, this distinction matters. Current UK medicines information lists AbbVie botulinum toxin type A under the BOTOX name rather than Vistabel. If a clinic refers to Vistabel, ask which exact medicine will be prescribed and administered in the UK.

If you want a broader explanation of the treatment category, read our Botox guide.

What is in Vistabel?

Vistabel contains botulinum toxin type A, a medicine that temporarily reduces signalling between nerves and selected muscles.

When used for facial lines, treatment is directed at specific muscles involved in facial movement. Reducing activity in these muscles can temporarily soften the appearance of certain movement-related lines.

The effect is temporary. The appropriate treatment area, dose and whether treatment is suitable depend on an individual assessment and the specific product being prescribed.

Is Vistabel the same as Botox?

Vistabel and Botox are closely related brand names associated with botulinum toxin type A products developed by Allergan, which is now part of AbbVie.

However, the names should not automatically be treated as interchangeable in patient information. Brand names, product licences and approved indications differ between countries.

In current UK medicines information, AbbVie lists its botulinum toxin type A medicine as BOTOX. VISTABEL continues to be used as an aesthetic product name in a number of European markets.

This is one reason to ask a practitioner for the exact name of the medicine being proposed rather than simply asking whether they “use Botox”.

What is Vistabel used for?

Vistabel has been authorised in European markets for the temporary improvement of particular facial lines caused by muscle movement. The exact authorised indications depend on the country and current product licence.

These can include areas such as:

• vertical lines between the eyebrows, often called glabellar or frown lines;

• crow's feet at the outer corners of the eyes;

• forehead lines.

This does not mean every facial or body treatment involving botulinum toxin is an authorised Vistabel indication.

Treatment of other concerns may involve a different product, a different authorised indication or, in some circumstances, use outside a medicine's licensed indication. A practitioner should explain what is being proposed during consultation.

How does Vistabel work?

Botulinum toxin type A acts at the connection between a nerve and a muscle. It reduces the release of acetylcholine, a chemical messenger involved in signalling the muscle to contract.

The treated muscle therefore contracts less strongly for a temporary period. In aesthetic treatment, this may reduce the visibility of lines that become more noticeable during repeated facial movement.

This effect gradually wears off as nerve-to-muscle activity recovers.

Vistabel, Allergan and AbbVie

Vistabel was developed within the Allergan botulinum toxin portfolio.

Allergan itself has a long history in pharmaceutical and aesthetic medicine, but an extensive corporate timeline is not necessary when deciding whether a treatment may be appropriate. The most relevant current point is that AbbVie completed its acquisition of Allergan in 2020, and Allergan Aesthetics now operates within AbbVie.

The Vistabel name continues to appear in Allergan Aesthetics and AbbVie product information in several European countries.

Vistabel versus other botulinum toxin brands

Vistabel is not the only botulinum toxin type A product used in aesthetic medicine. Different products have their own formulations, licensed indications and dosing systems.

The units used for one botulinum toxin preparation should not simply be treated as equivalent to units of another product.

For example, Azzalure is another botulinum toxin type A medicine with its own product-specific dosing and indications.

The brand alone should not determine your treatment decision. More relevant questions include why a particular medicine is being proposed, whether it is authorised for use in the UK, what indication is being treated and who is responsible for prescribing and administering it.

Is Vistabel better than other Botox brands?

There is no useful basis for saying that Vistabel is automatically “better” simply because of its manufacturer or brand name.

Different botulinum toxin products are separate medicines. Their units are product-specific, and treatment decisions should be based on the medicine, indication, practitioner assessment and individual circumstances rather than a simple brand ranking.

A practitioner should be able to explain why a particular product is being considered for you.

What should you check before treatment?

Before having a botulinum toxin treatment, ask:

• What is the exact product name?

• Is the medicine authorised for use in the UK?

• What is it being used to treat?

• Is the proposed use within the product's licensed indication?

• Who will prescribe it?

• Who will perform the injections?

• What relevant training and experience does the practitioner have?

• What risks and limitations apply?

• What follow-up is available if you have concerns?

Do not rely on the word “Botox” alone to identify what product you are receiving.